Research output

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

    Research areas

  • Hypoxia-activated prodrugs, Phase III clinical trial, Biomarker, Hypoxia, C P450 REDUCTASE, POSITRON-EMISSION-TOMOGRAPHY, SQUAMOUS-CELL CARCINOMAS, OXYGEN-ENHANCED MRI, TUMOR HYPOXIA, ANTITUMOR-ACTIVITY, NECK-CANCER, LUNG-CANCER, EXTRAVASCULAR TRANSPORT, EVOFOSFAMIDE TH-302
View graph of relations

Details

Original languageEnglish
Pages (from-to)62-69
Number of pages8
JournalClinical and Translational Radiation Oncology
Volume15
DOIs
Publication statusPublished - Feb 2019